Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9774475 | 1.00 | HCAR2 (0.51) | HCAR2ALOX5TRPM8MTORALDH1A1 | |
| SCHEMBL4707913 | 1.00 | HCAR2 (0.51) | HCAR2ALOX5TRPM8MTORALDH1A1 | |
| SCHEMBL20847151 | 0.87 | HCAR2 (0.53) | HCAR2ALOX5ALDH1A1TP53HSD17B10 | |
| SCHEMBL12436367 | 0.81 | HCAR2 (0.54) | HCAR2ALOX5MTORALDH1A1TP53 | |
| SCHEMBL10838224 | 0.80 | HCAR2 (0.53) | HCAR2ALOX5ALDH1A1TP53HSD17B10 | |
| SCHEMBL9728263 | 0.79 | HCAR2 (0.51) | HCAR2ALOX5ALDH1A1TP53HSD17B10 | |
| SCHEMBL26222316 | 0.77 | HCAR2 (0.50) | HCAR2ALOX5ALDH1A1TP53HSD17B10 | |
| SCHEMBL20846878 | 0.77 | HCAR2 (0.50) | HCAR2ALOX5ALDH1A1TP53HSD17B10 | |
| SCHEMBL3625234 | 0.77 | HCAR2 (0.61) | HCAR2ALOX5ALDH1A1TP53HSD17B10 | |
| SCHEMBL3786370 | 0.77 | HCAR2 (0.61) | HCAR2ALOX5ALDH1A1TP53HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2914590-B1 | NOVEL ROCK INHIBITORS | PH PHARMA CO LTD (KR) | 2016-11-30 | — | — | EP | disclosed |
| US-9394286-B2 | Rock inhibitors | AMAKEM NV (BE) | 2016-07-19 | — | — | US | disclosed |
| US-9174939-B2 | Soft rock inhibitors | AMAKEM NV (BE) | 2015-11-03 | — | — | US | disclosed |
| US-20150299173-A1 | NOVEL ROCK INHIBTORS | AMAKEM NV (BE) | 2015-10-22 | — | — | US | disclosed |
| EP-2914590-A1 | NOVEL ROCK INHIBITORS | Amakem NV (BE) | 2015-09-09 | — | — | EP | disclosed |
| US-9126933-B2 | Soft PDE4 inhibitors | AMAKEM NV (BE) | 2015-09-08 | — | — | US | disclosed |
| US-9079858-B2 | Rock kinase inhibitors | AMAKEM NV (BE) | 2015-07-14 | — | — | US | disclosed |
| US-9073905-B2 | Rock inhibitors | AMAKEM NV (BE) | 2015-07-07 | — | — | US | disclosed |
| US-9067889-B2 | Biphenylcarboxamides as ROCK kinase inhibitors | AMAKEM NV (BE) | 2015-06-30 | — | — | US | disclosed |
| US-20140371268-A1 | BIPHENYLCARBOXAMIDES AS ROCK KINASE INHIBITORS | AMAKEM NV (BE) | 2014-12-18 | — | — | US | disclosed |
| WO-2013004709-A1 | INDOLYLMALEIMIDES AS SOFT PAN-PKC INHIBITORS | AMAKEM NV (BE) | 2013-01-10 | — | — | WO | disclosed |
| EP-2542528-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | Amakem NV (BE) | 2013-01-09 | — | — | EP | disclosed |
| US-20120322801-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2012-12-20 | — | — | US | disclosed |
| WO-2012156467-A1 | NOVEL PKC INHIBITORS | AMAKEM NV (BE) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012146724-A2 | NOVEL ROCK INHIBITORS | AMAKEM NV (BE) | 2012-11-01 | — | — | WO | disclosed |
| WO-2011107608-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2011-09-09 | — | — | WO | disclosed |
| US-20100190788-A1 | Amide derivatives as kinase inhitors | DEVGEN N.V. (BE) | 2010-07-29 | — | — | US | disclosed |
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20090233960-A1 | Kinase Inhibitors | DEVGEN NV (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371268-A1 | BIPHENYLCARBOXAMIDES AS ROCK KINASE INHIBITORS | ROCK2, ROCK1, CIT | HCAR2 1050/4885ALOX5 1036/4885TRPM8 3919/4885 |
| US-20090233960-A1 | Kinase Inhibitors | ROCK1, MAP3K1, MAP3K11 | HCAR2 1529/4885ALOX5 3947/4885TRPM8 2870/4885 |
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | MAP3K1, CDK1, CDK2 | HCAR2 896/4885ALOX5 4220/4885TRPM8 2139/4885 |
| US-20100190788-A1 | Amide derivatives as kinase inhitors | MAP3K1, MAPK1, MAP3K21 | HCAR2 731/4885ALOX5 4189/4885TRPM8 3428/4885 |
| US-20120322801-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | ROCK1, ROCK2, CIT | HCAR2 790/4885ALOX5 584/4885TRPM8 4306/4885 |
| US-20150299173-A1 | NOVEL ROCK INHIBTORS | ROCK1, ROCK2, CIT | HCAR2 1618/4885ALOX5 1944/4885TRPM8 3813/4885 |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | MAP3K1, CDK1, CDK2 | HCAR2 896/4885ALOX5 4220/4885TRPM8 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.